Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 25, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 130,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,534 pence per share; lowest price paid was 1,518.5 pence per share.
- Treasury Holdings (Settled): 497,621,327 shares, representing 9.20% of total issued share capital.
- Treasury Holdings (Including Unsettled): 498,081,327 shares, representing 10.15% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,909,281,017 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 130,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (497,621,327 settled) against the Company's latest annual report.
- Confirm the percentage of total voting rights held in Treasury (10.15% including unsettled shares) for disclosure threshold calculations.
- Check the remaining authority for share repurchases under the mandate granted on May 3, 2012.
- Note that this filing does not contain operational or financial performance metrics for the period.